Targacept (TRGT) 2.78 $TRGT
Targacept to Report Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Wed Jul 30, 7:30AM CDT
Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced it will report financial results for the second quarter of 2014 on Wednesday, August 6, 2014, before the U.S. financial markets open.
Hot Stock: Targacept, Shares Drop 25.5% (TRGT)
Comtex SmarTrend(R) - Tue Jul 29, 10:09AM CDT
Targacept (NASDAQ:TRGT) is one of today's worst performing low-priced stocks, down 25.5% to $2.92 on 2.2x average daily volume. Targacept has traded 751,000 shares thus far today, vs. average volume of 345,000 shares per day. The stock has underperformed the Dow (-25.5% to the Dow's 0.3%) and underperformed the S&P 500 (-25.5% to the S&P's 0.1%) during today's trading.
Targacept to Discontinue TC-5214 Overactive Bladder Program
Business Wire - Mon Jul 28, 3:35PM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced top-line results from a Phase 2b clinical trial of TC-5214 as a treatment for overactive bladder (OAB). In the trial, the high dose of TC-5214 demonstrated mixed results on the co-primary endpoints by providing a statistically significant reduction in micturition frequency (p=0.033) and an improvement that did not reach statistical significance on episodes of urinary incontinence (p=0.379) per 24 hours, after 12 weeks of treatment. As a consequence of these results, Targacept is discontinuing further development of TC-5214 in OAB.
Technical Update, Leadership Appointments, Therapy Approvals, Notifications, and Clinical Trial Results - Analyst Notes on Biogen, Medivation, BioMarin, Acorda and Targacept
PR Newswire - Thu Jul 17, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Medivation, Inc. (NASDAQ: MDVN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Acorda Therapeutics, Inc. (NASDAQ: ACOR) and Targacept, Inc. (NASDAQ: TRGT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4882-100free.
Targacept Down 7.6%, Shares Slide into the Red (TRGT)
Comtex SmarTrend(R) - Tue Jul 15, 11:38AM CDT
Targacept (NASDAQ:TRGT) is one of today's worst performing low-priced stocks, down 7.6% to $4.08 on 1.2x average daily volume. Targacept has traded 318,000 shares thus far today, vs. average volume of 272,000 shares per day. The stock has underperformed the Dow (-7.6% to the Dow's -0.1%) and underperformed the S&P 500 (-7.6% to the S&P's -0.4%) during today's trading.
Targacept Phase 2b Clinical Trial in Alzheimer's Disease Does Not Show Superiority of TC-1734 Over Donepezil
Business Wire - Mon Jul 14, 2:06PM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer's disease. In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer's disease, after 52 weeks of treatment. The trial did not include a placebo arm and was not designed to determine whether TC-1734 is equivalent to donepezil. The co-primary endpoints for the study were measures of cognitive function and global function. Consistent with previous clinical results, TC-1734 exhibited a benign safety and tolerability profile.
Age Related Memory Impairment Clinical Trials Review, H1, 2014
M2 - Mon Jun 30, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tn8pmb/age_related) has announced the addition of the "Age Related Memory Impairment Global Clinical Trials Review, H1, 2014" report to their offering. Age Related Memory Impairment Global Clinical Trials Review, H1, 2014" provides data on the Age Related Memory Impairment clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Age Related Memory Impairment. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Age Related Memory Impairment. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Age Related Memory Impairment Therapeutics Clinical Trials - Orexo AB - Helicon Therapeutics, Inc. - Dart NeuroScience LLC - Targacept, Inc. - Martek Biosciences Corporation (Inactive) - Lexicon Pharmaceuticals, Inc. - Bayer AG - Allergan, Inc. - Accera, Inc. - Central Drug Research Institute - University of Cincinnati - The University of Arizona - University Hospital, Toulouse - University of California, Los Angeles - University of Southern California - National Institute on Aging - Queen's University - Stanford University - University of Florida For more information visit http://www.researchandmarkets.com/research/tn...ge_related
Targacept Initiates Exploratory Study of TC-6499 in Diabetic Gastroparesis
Business Wire - Wed Jun 25, 7:55AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced the initiation of a Phase 1/2 exploratory study of TC-6499 as a treatment for gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine. TC-6499 is a novel small molecule that modulates the activity of the alpha3beta4 and other neuronal nicotinic receptors (NNRs). The alpha3beta4 NNR is located throughout the gastrointestinal tract and, when modulated, is believed to increase cholinergic tone, which in turn leads to increased motility.
Targacept to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 7:55AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the 13th Annual Needham Healthcare Conference at the Westin New York Grand Central Hotel in New York City on Wednesday, April 9, 2014 at 1:40 p.m. Eastern Time.
Targacept to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference at The Boston Marriott Copley Place in Boston, Massachusetts on Wednesday, March 5, 2014 at 8:00 a.m. Eastern Time.
Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Targacept Reports Fourth Quarter and 2013 Financial Results
Business Wire - Thu Feb 13, 6:30AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today reported its financial results for the fourth quarter and year ended December 31, 2013.
First American Financial Reports Results for the Fourth Quarter and Full Year of 2013
Business Wire - Thu Feb 13, 6:00AM CST
First American Financial Corporation (NYSE: FAF), a leading global provider of title insurance, settlement services and risk solutions for real estate transactions, today announced financial results for the fourth quarter and year ended Dec. 31, 2013.
10-K: MICROSTRATEGY INC
Edgar Online - Wed Feb 12, 3:52PM CST
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Silverpop Launches 2014 Digital Marketing Roadshow Aimed at Helping Marketers Navigate the Customer-Driven World
PR Newswire - Wed Feb 12, 8:20AM CST
Silverpop(TM), a leading provider of digital marketing software that enables personalized customer experiences, today announces the 2014 launch of Digital Marketing University. The series is a global, multi-city educational roadshow aimed at helping marketers of all types thrive in today's ever changing, customer-driven landscape. Silverpop thought leaders and experts from several Silverpop technology and consulting partners will lead discussions to guide marketers along their pursuit to provide customers with a unified, multichannel experience.
Hot Stock: Targacept, Shares Gain 5.5% (TRGT)
Comtex SmarTrend(R) - Mon Feb 10, 11:42AM CST
Targacept (NASDAQ:TRGT) is one of today's best performing low-priced stocks, up 5.5% to $4.96 on 1.1x average daily volume. Targacept has traded 312,000 shares thus far today, vs. average volume of 294,000 shares per day. The stock has outperformed the Dow (5.5% to the Dow's -0.1%) and outperformed the S&P 500 (5.5% to the S&P's -0.1%) during today's trading.
Targacept Completes Recruitment in Phase 2b Overactive Bladder Trial of TC-5214
Business Wire - Mon Feb 10, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB). The company expects to report top-line results from the study in mid-2014. TC-5214 acts potently on alpha3beta4 and other neuronal nicotinic receptors (NNRs) located in or around the bladder that are believed to play a key role in bladder contraction and signaling of the urge to urinate.
5 Stocks Poised for Breakouts
at The Street - Fri Feb 07, 1:52PM CST
These stocks are ready to break out and trade higher from current levels.
Targacept to Report Fourth Quarter and 2013 Financial Results on February 13, 2014
Business Wire - Thu Feb 06, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced it will report financial results for the fourth quarter and year ended December 31, 2013 on Thursday, February 13, 2014, before the U.S. financial markets open.
Targacept to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the 16th Annual BIO CEO & Investor Conference at The Waldorf Astoria New York in New York City on Tuesday, February 11, 2014 at 2:30 p.m. Eastern Time.
Targacept to Report Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Wed Jul 30, 7:30AM CDT
Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced it will report financial results for the second quarter of 2014 on Wednesday, August 6, 2014, before the U.S. financial markets open.
Hot Stock: Targacept, Shares Drop 25.5% (TRGT)
Comtex SmarTrend(R) - Tue Jul 29, 10:09AM CDT
Targacept (NASDAQ:TRGT) is one of today's worst performing low-priced stocks, down 25.5% to $2.92 on 2.2x average daily volume. Targacept has traded 751,000 shares thus far today, vs. average volume of 345,000 shares per day. The stock has underperformed the Dow (-25.5% to the Dow's 0.3%) and underperformed the S&P 500 (-25.5% to the S&P's 0.1%) during today's trading.
Targacept to Discontinue TC-5214 Overactive Bladder Program
Business Wire - Mon Jul 28, 3:35PM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced top-line results from a Phase 2b clinical trial of TC-5214 as a treatment for overactive bladder (OAB). In the trial, the high dose of TC-5214 demonstrated mixed results on the co-primary endpoints by providing a statistically significant reduction in micturition frequency (p=0.033) and an improvement that did not reach statistical significance on episodes of urinary incontinence (p=0.379) per 24 hours, after 12 weeks of treatment. As a consequence of these results, Targacept is discontinuing further development of TC-5214 in OAB.
Technical Update, Leadership Appointments, Therapy Approvals, Notifications, and Clinical Trial Results - Analyst Notes on Biogen, Medivation, BioMarin, Acorda and Targacept
PR Newswire - Thu Jul 17, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Medivation, Inc. (NASDAQ: MDVN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Acorda Therapeutics, Inc. (NASDAQ: ACOR) and Targacept, Inc. (NASDAQ: TRGT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4882-100free.
Targacept Down 7.6%, Shares Slide into the Red (TRGT)
Comtex SmarTrend(R) - Tue Jul 15, 11:38AM CDT
Targacept (NASDAQ:TRGT) is one of today's worst performing low-priced stocks, down 7.6% to $4.08 on 1.2x average daily volume. Targacept has traded 318,000 shares thus far today, vs. average volume of 272,000 shares per day. The stock has underperformed the Dow (-7.6% to the Dow's -0.1%) and underperformed the S&P 500 (-7.6% to the S&P's -0.4%) during today's trading.
Targacept Phase 2b Clinical Trial in Alzheimer's Disease Does Not Show Superiority of TC-1734 Over Donepezil
Business Wire - Mon Jul 14, 2:06PM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer's disease. In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer's disease, after 52 weeks of treatment. The trial did not include a placebo arm and was not designed to determine whether TC-1734 is equivalent to donepezil. The co-primary endpoints for the study were measures of cognitive function and global function. Consistent with previous clinical results, TC-1734 exhibited a benign safety and tolerability profile.
Age Related Memory Impairment Clinical Trials Review, H1, 2014
M2 - Mon Jun 30, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tn8pmb/age_related) has announced the addition of the "Age Related Memory Impairment Global Clinical Trials Review, H1, 2014" report to their offering. Age Related Memory Impairment Global Clinical Trials Review, H1, 2014" provides data on the Age Related Memory Impairment clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Age Related Memory Impairment. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Age Related Memory Impairment. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Age Related Memory Impairment Therapeutics Clinical Trials - Orexo AB - Helicon Therapeutics, Inc. - Dart NeuroScience LLC - Targacept, Inc. - Martek Biosciences Corporation (Inactive) - Lexicon Pharmaceuticals, Inc. - Bayer AG - Allergan, Inc. - Accera, Inc. - Central Drug Research Institute - University of Cincinnati - The University of Arizona - University Hospital, Toulouse - University of California, Los Angeles - University of Southern California - National Institute on Aging - Queen's University - Stanford University - University of Florida For more information visit http://www.researchandmarkets.com/research/tn...ge_related
Targacept Initiates Exploratory Study of TC-6499 in Diabetic Gastroparesis
Business Wire - Wed Jun 25, 7:55AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced the initiation of a Phase 1/2 exploratory study of TC-6499 as a treatment for gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine. TC-6499 is a novel small molecule that modulates the activity of the alpha3beta4 and other neuronal nicotinic receptors (NNRs). The alpha3beta4 NNR is located throughout the gastrointestinal tract and, when modulated, is believed to increase cholinergic tone, which in turn leads to increased motility.
Targacept to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 7:55AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the 13th Annual Needham Healthcare Conference at the Westin New York Grand Central Hotel in New York City on Wednesday, April 9, 2014 at 1:40 p.m. Eastern Time.
Targacept to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference at The Boston Marriott Copley Place in Boston, Massachusetts on Wednesday, March 5, 2014 at 8:00 a.m. Eastern Time.
Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Targacept Reports Fourth Quarter and 2013 Financial Results
Business Wire - Thu Feb 13, 6:30AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today reported its financial results for the fourth quarter and year ended December 31, 2013.
First American Financial Reports Results for the Fourth Quarter and Full Year of 2013
Business Wire - Thu Feb 13, 6:00AM CST
First American Financial Corporation (NYSE: FAF), a leading global provider of title insurance, settlement services and risk solutions for real estate transactions, today announced financial results for the fourth quarter and year ended Dec. 31, 2013.
10-K: MICROSTRATEGY INC
Edgar Online - Wed Feb 12, 3:52PM CST
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Silverpop Launches 2014 Digital Marketing Roadshow Aimed at Helping Marketers Navigate the Customer-Driven World
PR Newswire - Wed Feb 12, 8:20AM CST
Silverpop(TM), a leading provider of digital marketing software that enables personalized customer experiences, today announces the 2014 launch of Digital Marketing University. The series is a global, multi-city educational roadshow aimed at helping marketers of all types thrive in today's ever changing, customer-driven landscape. Silverpop thought leaders and experts from several Silverpop technology and consulting partners will lead discussions to guide marketers along their pursuit to provide customers with a unified, multichannel experience.
Hot Stock: Targacept, Shares Gain 5.5% (TRGT)
Comtex SmarTrend(R) - Mon Feb 10, 11:42AM CST
Targacept (NASDAQ:TRGT) is one of today's best performing low-priced stocks, up 5.5% to $4.96 on 1.1x average daily volume. Targacept has traded 312,000 shares thus far today, vs. average volume of 294,000 shares per day. The stock has outperformed the Dow (5.5% to the Dow's -0.1%) and outperformed the S&P 500 (5.5% to the S&P's -0.1%) during today's trading.
Targacept Completes Recruitment in Phase 2b Overactive Bladder Trial of TC-5214
Business Wire - Mon Feb 10, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB). The company expects to report top-line results from the study in mid-2014. TC-5214 acts potently on alpha3beta4 and other neuronal nicotinic receptors (NNRs) located in or around the bladder that are believed to play a key role in bladder contraction and signaling of the urge to urinate.
5 Stocks Poised for Breakouts
at The Street - Fri Feb 07, 1:52PM CST
These stocks are ready to break out and trade higher from current levels.
Targacept to Report Fourth Quarter and 2013 Financial Results on February 13, 2014
Business Wire - Thu Feb 06, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced it will report financial results for the fourth quarter and year ended December 31, 2013 on Thursday, February 13, 2014, before the U.S. financial markets open.
Targacept to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 7:55AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the 16th Annual BIO CEO & Investor Conference at The Waldorf Astoria New York in New York City on Tuesday, February 11, 2014 at 2:30 p.m. Eastern Time.
